Sinovant Sciences and Renexxion have initiated a collaboration for the development of naronapride, an investigational gastrointestinal prokinetic, in China. Renexxion has granted Sinovant an exclusive license for the development and commercialization of naronapride in China, Hong Kong, Macau, and Taiwan in exchange for license fee payments, commercial milestones, and royalties.   Sinovant will initially develop naronapride in irritable bowel syndrome with constipation (IBS-C), a condition that...